Canadian clinical-stage biopharmaceutical company, Xenon Pharmaceuticals Inc., is dedicated to developing treatments for patients with neurological disorders. The company's clinical development pipeline features two key candidates: XEN496, a potassium channel opener in Phase III clinical trials to treat KCNQ2 developmental and epileptic encephalopathy; and XEN1101, another potassium channel opener in Phase II clinical trial to treat epilepsy and other neurological disorders. Alongside these proprietary development programs, Xenon is exploring potential treatments for SCN8A developmental and epileptic encephalopathy and other indications, such as adult focal epilepsy, with its product candidate NBI-921352, a selective Nav1.6 sodium channel inhibitor, now in Phase II clinical trials. Notably, the company has licensed and collaborated with Neurocrine Biosciences to develop treatments for epilepsy. Xenon Pharmaceuticals was founded in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals's ticker is XENE
The company's shares trade on the NASDAQ stock exchange
They are based in Burnaby, British Columbia
There are 51-200 employees working at Xenon Pharmaceuticals
It is xenon-pharma.com
Xenon Pharmaceuticals is in the Healthcare sector
Xenon Pharmaceuticals is in the Biotechnology industry
The following five companies are Xenon Pharmaceuticals's industry peers: